AR058439A1 - Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR058439A1 AR058439A1 ARP060103235A ARP060103235A AR058439A1 AR 058439 A1 AR058439 A1 AR 058439A1 AR P060103235 A ARP060103235 A AR P060103235A AR P060103235 A ARP060103235 A AR P060103235A AR 058439 A1 AR058439 A1 AR 058439A1
- Authority
- AR
- Argentina
- Prior art keywords
- diyl
- alkyl
- group
- represented
- alkoxy
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- -1 1,2,4-triazin-3,5-diyl Chemical group 0.000 abstract 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 abstract 1
- YHKWFDPEASWKFQ-UHFFFAOYSA-N 3-nitrobenzene-1,2-diol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1O YHKWFDPEASWKFQ-UHFFFAOYSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 210000001428 peripheral nervous system Anatomy 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical group [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
Abstract
Los compuestos tienen propiedades farmacéuticas en el tratamiento de algunos trastornos del sistema nervioso central y periférico. Procesos de preparacion y composiciones farmacéuticas que los comprenden. Reivindicacion 1: Un compuesto de formula (1) caracterizado porque R1 y R2, independientemente uno de otro, son hidrogeno o un grupo que puede hidrolizarse bajo condiciones fisiologicas, alcanilo inferior o arilo opcionalmente sustituido ; X representa un grupo metileno; Y representa un átomo de oxígeno, nitrogeno, o azufre; n representa el numero 0, 1, 2, o 3 y m representa un numero 0 o 1; R3 representa un grupo de N-oxido de piridina de acuerdo con la formula A, B o C, que se conecta como lo indica el enlace no marcado (A-B-C) donde R4, R5, R6 y R7 independientemente uno del otro, representan hidrogeno, C1-C6-alquilo, C1-C6-tioalquilo, C1-C6-alcoxilo, C6-C12-ariloxilo o un grupo C6-C23-tioarilo, C1-C6 alcanoilo un grupo C7-C13-arilo, amino, C1-C6alquilamino, C1-C6- dialquilamino, C3-C12-cicloalquilamino, C3-C12-cicloalquilamino, C3-C12-heterociclo-alquilamino, C1-C6-alquilsufonilo, C6-C12-arilsulfonilo, halogeno, C1-C6-haloalquilo, triflorometilo, ciano, nitro o un grupo heteroarilo; o dos más de los residuos R4, R5, R6 y R7 tomados juntos representan anillos alifáticos o heteroalifáticos, o anillos aromáticos o heteroaráticos, y donde P representa una unidad central, que preferiblemente es una unidad plana, y que aun m{as preferiblemente se selecciona entre los regioisomeros de 1, 3, 4 -oxadiol-2-5-diilo, 1,2,4-oxadiazol-3-5-diilo, 4-metil-4H-1,2,4-triazol-3-5-diilo, 1, 3,5-triazin-2-4-diilo, 1,2,4-triazin-3,5-diilo, 2H-tetrazol,-2,5-diilo, 1,2,3-tiadiazol-4,5-diilo, 1-alquil-3-(alcoxicarbonil)- 1H-pirrol-2,5-diilo, donde el alquilo es representado por metilo, etilo, n-propilo y n-butilo y donde el alcoxilo es representado por metoxilo, etoxilo, n-propoxilo e isopropoxilo, 1-alquil-1H-pirrol-2,5-diilo donde el alquilo es representado por metilo, etilo, n-propilo y n-butilo, tiazol, -2,4diili, 1-H-pirazol-1,5-diilo, pirimidin-2,4-diilo, oxazol-2,4-diilo, carbonilo, 1H-imidazol-1,5-diilo, isoxazol-3,5-diilo, furan-2,4-diilo, 3-alcoxicarbonilfuran-2,4-diilo, donde el alcoxilo es representado por metoxilo, etoxilo, n-propoxilo e isopropoxilo, bencen-1,3-diilo y (Z)-1-cianoeten-1,2-diilo, y donde los regioisomeros de la unidad central incluyen ambos regioisomeros realizables con un intercambio de la porcion de nitrocatecol y la porcion -(X)n-(Y)m-R3.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0515327A GB0515327D0 (en) | 2005-07-26 | 2005-07-26 | Comt inhibitors |
| EP06008203 | 2006-04-20 | ||
| EP06011073 | 2006-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR058439A1 true AR058439A1 (es) | 2008-02-06 |
Family
ID=37056522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103235A AR058439A1 (es) | 2005-07-26 | 2006-07-26 | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US8168793B2 (es) |
| EP (2) | EP2301934A1 (es) |
| JP (3) | JP5517453B2 (es) |
| KR (1) | KR101370280B1 (es) |
| CN (1) | CN102816157B (es) |
| AR (1) | AR058439A1 (es) |
| AU (1) | AU2006272978B2 (es) |
| BR (1) | BRPI0613859B8 (es) |
| CA (1) | CA2616377C (es) |
| CY (2) | CY1116754T1 (es) |
| DK (1) | DK1907382T3 (es) |
| ES (1) | ES2545178T3 (es) |
| HU (2) | HUE025466T2 (es) |
| IL (1) | IL188913A (es) |
| LT (1) | LTC1907382I2 (es) |
| LU (1) | LU93327I2 (es) |
| NL (1) | NL300848I2 (es) |
| NO (2) | NO341886B1 (es) |
| NZ (1) | NZ565460A (es) |
| PL (1) | PL1907382T3 (es) |
| PT (1) | PT1907382E (es) |
| SI (1) | SI1907382T1 (es) |
| WO (1) | WO2007013830A1 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL169855A (en) * | 2005-07-25 | 2014-05-28 | Elta Systems Ltd | A system and method for locating a receiver location |
| KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체 |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| BRPI0720043A2 (pt) | 2006-12-15 | 2014-01-07 | Abbott Lab | Composto oxadiazol |
| JP5517629B2 (ja) * | 2007-01-31 | 2014-06-11 | ノヴィファーマ，エス．アー． | Ｃｏｍｔ阻害剤用の投薬計画 |
| CN101965334A (zh) * | 2007-10-24 | 2011-02-02 | 比艾尔-坡特拉有限公司 | 新的前体 |
| CN101965339B (zh) * | 2007-12-25 | 2013-08-14 | 橘生药品工业株式会社 | 儿茶酚衍生物、含有其的药物组合物、儿茶酚衍生物的应用以及药物组合物的应用 |
| JP2011514380A (ja) | 2008-03-17 | 2011-05-06 | バイアル−ポルテラ アンド シーエー，エス．エー． | ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形 |
| KR20180095135A (ko) * | 2008-07-29 | 2018-08-24 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 화합물 및 그 약학적 조성물 |
| DK2413913T3 (da) * | 2009-04-01 | 2022-06-13 | Bial Portela & Ca Sa | Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf |
| RU2701731C2 (ru) * | 2009-04-01 | 2019-10-01 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
| JP5707063B2 (ja) * | 2009-06-18 | 2015-04-22 | キッセイ薬品工業株式会社 | 新規なカテコール誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP5433505B2 (ja) * | 2009-06-18 | 2014-03-05 | キッセイ薬品工業株式会社 | ニトロカテコール誘導体の製造方法およびその製造中間体 |
| JP5529639B2 (ja) * | 2009-06-18 | 2014-06-25 | キッセイ薬品工業株式会社 | 新規なカテコール−ｏ−メチルトランスフェラーゼ阻害剤 |
| WO2011069075A2 (en) * | 2009-12-04 | 2011-06-09 | Grant Jon E | Treating impulse control disorders with catechol-o- methyl-transferase inhibitors |
| WO2011107653A2 (en) | 2010-03-04 | 2011-09-09 | Orion Corporation | Method for treating parkinson's disease |
| KR101799429B1 (ko) * | 2010-05-03 | 2017-11-21 | 에스케이바이오팜 주식회사 | 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| JP2013053559A (ja) * | 2011-09-05 | 2013-03-21 | Suzuki Motor Corp | 車両の衝突被害軽減制御装置 |
| BR112014014341A2 (pt) | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
| TWI638802B (zh) | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚ｏ－甲基轉移酶活性抑制化合物 |
| CN104582488A (zh) * | 2012-06-30 | 2015-04-29 | 美国陶氏益农公司 | N-取代的磺基肟吡啶n-氧化物的制备方法 |
| US10335786B2 (en) * | 2013-05-31 | 2019-07-02 | Pixcell Medical Technologies Ltd. | Cartridge for preparing a sample fluid containing cells for analysis |
| ES2676585T3 (es) | 2013-08-28 | 2018-07-23 | Medivation Technologies Llc | Compuestos heterocíclicos y métodos de uso |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
| US10189826B2 (en) | 2015-03-04 | 2019-01-29 | Medivation Technologies Llc | Heterocyclic compounds and methods of use |
| WO2016141159A1 (en) | 2015-03-04 | 2016-09-09 | Medivation Technologies, Inc. | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
| AU2016282121B2 (en) * | 2015-06-23 | 2020-12-24 | National Institute Of Biological Sciences, Beijing | FTO inhibitors |
| JP2020158391A (ja) * | 2017-06-13 | 2020-10-01 | 株式会社富士薬品 | 新規ニトロカテコール誘導体 |
| GB2563858A (en) * | 2017-06-27 | 2019-01-02 | Azad Pharmaceutical Ingredients Ag | New route of synthesis for opicapone |
| MX2020006283A (es) * | 2017-12-18 | 2020-12-09 | Unichem Lab Ltd | Proceso para la preparación de opicapona y sus intermediarios. |
| WO2020072884A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
| US12097193B2 (en) | 2018-10-05 | 2024-09-24 | Bial—Portela & Ca, S.A. | Methods for the administration of COMT inhibitors |
| CN120478288A (zh) | 2020-03-13 | 2025-08-15 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| GB202204798D0 (en) | 2022-04-01 | 2022-05-18 | Bial Portela & Ca Sa | Prodrugs of opicapone |
| GB202219669D0 (en) | 2022-12-23 | 2023-02-08 | Bial Portela & Ca Sa | Processes and intermediates for synthesising opicapone |
| WO2024260874A1 (en) | 2023-06-19 | 2024-12-26 | Medichem, S.A. | Process for preparing opicapone |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1532178A (en) | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
| FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
| US3647809A (en) | 1968-04-26 | 1972-03-07 | Chinoin Gyogyszer Es Vegyeszet | Certain pyridyl-1 2 4-oxadiazole derivatives |
| US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
| US4264573A (en) | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
| US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
| EP0072654A3 (en) | 1981-08-19 | 1983-08-24 | Ecomax (U.K.) Limited | Delivery nozzle for use with a mineral fibre pumping apparatus |
| DK175069B1 (da) * | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| YU213587A (en) | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
| US5206372A (en) | 1990-06-05 | 1993-04-27 | Shell Research Limited | Preparation of 2-chloropyridine derivatives |
| DE69013689T2 (de) | 1990-11-29 | 1995-03-02 | Wei Ming Pharmaceutical Mfg Co | Hilfsträger für direkte Verpressung. |
| CA2126976A1 (en) | 1991-12-31 | 1993-07-08 | Hisashi Takasugi | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
| PT652868E (pt) * | 1992-07-28 | 2005-01-31 | Aventis Pharma Ltd | Inibidores da fosfodiesterase do amp ciclico |
| DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
| US6206110B1 (en) | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
| EP1114039A1 (en) | 1998-09-18 | 2001-07-11 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
| GB2344819A (en) * | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| IL131037A (en) | 1999-07-22 | 2004-06-20 | Israel Atomic Energy Comm | Method for making threedimensional photonic band-gap crystals |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| EP1210344B1 (en) | 1999-08-19 | 2005-10-19 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
| SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
| DE10029201A1 (de) | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
| GB2363792A (en) * | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
| GB0015228D0 (en) * | 2000-06-21 | 2000-08-16 | Portela & Ca Sa | Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders |
| WO2002017175A1 (en) | 2000-08-24 | 2002-02-28 | Sagawa Express Co., Ltd. | Card payment method for service charge concerning to physical distribution or transportation |
| CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
| EP1356046B1 (en) | 2000-11-28 | 2009-10-14 | ZymoGenetics, L.L.C. | Cytokine receptor zcytor19 |
| US20040097555A1 (en) | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
| EP1354603A1 (en) | 2000-12-26 | 2003-10-22 | Takeda Chemical Industries, Ltd. | Concomitant drugs |
| ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
| EP1412327A2 (en) | 2001-05-30 | 2004-04-28 | LG Biomedical Institute | Inhibitors of protein kinase for the treatment of disease |
| JP2005504014A (ja) | 2001-06-08 | 2005-02-10 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された３−アリール−５−アリール−［１，２，４］−オキサジアゾール類および類似体、並びにその使用法 |
| WO2002100859A1 (en) * | 2001-06-12 | 2002-12-19 | Grelan Pharmaceutical Co., Ltd. | Pde iv inhibitors |
| CN1292749C (zh) | 2001-07-26 | 2007-01-03 | 默克专利股份有限公司 | 2－[5－(4－氟苯基)－3－吡啶基甲氨基甲基]苯并二氢吡喃及其生理学上可接受的盐的新用途 |
| JP4379853B2 (ja) | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
| CN100364531C (zh) | 2002-12-18 | 2008-01-30 | 西托维亚公司 | 3,5－二取代－[1,2,4]－二唑及类似物和其用途 |
| WO2004058163A2 (en) | 2002-12-23 | 2004-07-15 | Merck Frosst Canada & Co. | Pharmaceutical compositions and method of treating parkinson's disease |
| WO2005006945A2 (en) | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| TW200514776A (en) | 2003-08-06 | 2005-05-01 | Vertex Pharma | Aminotriazole compounds useful as inhibitors of protein kinases |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| US7300406B2 (en) | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7531556B2 (en) | 2004-04-28 | 2009-05-12 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
| DE202004011766U1 (de) | 2004-07-28 | 2004-10-14 | Enderle, Stefan | Roboterbausatz für einen autonomen mobilen Roboter und mit Hilfe dieses Bausatzes konstruierter Roboter |
| GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2006051154A1 (en) | 2004-11-10 | 2006-05-18 | Orion Corporation | Treatment of restless legs syndrome |
| WO2006061697A1 (en) | 2004-12-06 | 2006-06-15 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
| EP1833804A1 (en) | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
| US20080051441A1 (en) | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
| JP2008539195A (ja) | 2005-04-26 | 2008-11-13 | ノイロサーチ アクティーゼルスカブ | 新規のオキサジアゾール誘導体及びそれらの医学的使用 |
| US20060257473A1 (en) | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US7553964B2 (en) | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
| JP2007024970A (ja) | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
| US20090000437A1 (en) | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
| KR101370280B1 (ko) | 2005-07-26 | 2014-03-06 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | Ｃｏｍｔ 억제제로서의 니트로카테콜 유도체 |
| FR2889525A1 (fr) | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
| US20070048384A1 (en) | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
| US20090012170A1 (en) | 2005-09-21 | 2009-01-08 | Helena Nissinen | Treatment of symptoms of motor dysfunction |
| EP1954137A4 (en) | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| US8022075B2 (en) | 2005-11-30 | 2011-09-20 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
| GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
| US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| JP5517629B2 (ja) | 2007-01-31 | 2014-06-11 | ノヴィファーマ，エス．アー． | Ｃｏｍｔ阻害剤用の投薬計画 |
| EP2182809B1 (en) | 2007-08-27 | 2018-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
| CA2715802A1 (en) | 2008-02-28 | 2009-09-03 | Bial - Portela & C.A., S.A. | Pharmaceutical composition for poorly soluble drugs |
| JP2011514380A (ja) | 2008-03-17 | 2011-05-06 | バイアル−ポルテラ アンド シーエー，エス．エー． | ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形 |
| KR20180095135A (ko) | 2008-07-29 | 2018-08-24 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 화합물 및 그 약학적 조성물 |
| US8827197B2 (en) | 2008-11-04 | 2014-09-09 | Microgreen Polymers Inc | Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing |
| DK2413913T3 (da) | 2009-04-01 | 2022-06-13 | Bial Portela & Ca Sa | Farmaceutiske formuleringer omfattende nitrocatecholderivater og fremgangsmåder til fremstilling deraf |
| RU2701731C2 (ru) | 2009-04-01 | 2019-10-01 | Биал-Портела Энд Ка, С.А. | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения |
| US8294760B2 (en) | 2009-04-21 | 2012-10-23 | Samsung Techwin Co., Ltd. | Electronic part recognition apparatus and chip mounter having the same |
| WO2011107653A2 (en) | 2010-03-04 | 2011-09-09 | Orion Corporation | Method for treating parkinson's disease |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| BR112014014341A2 (pt) | 2011-12-13 | 2017-08-22 | Bial Portela & Ca Sa | Intermediário metilado, seu método de preparação e seus usos, e composição farmacêutica |
| WO2016083863A1 (en) | 2014-11-28 | 2016-06-02 | Bial - Portela & Ca, S.A. | Medicaments for slowing parkinson's disease |
-
2006
- 2006-07-26 KR KR1020087000434A patent/KR101370280B1/ko active Active
- 2006-07-26 AU AU2006272978A patent/AU2006272978B2/en active Active
- 2006-07-26 PL PL06769520T patent/PL1907382T3/pl unknown
- 2006-07-26 DK DK06769520.5T patent/DK1907382T3/en active
- 2006-07-26 SI SI200631969T patent/SI1907382T1/sl unknown
- 2006-07-26 WO PCT/PT2006/000020 patent/WO2007013830A1/en not_active Ceased
- 2006-07-26 CN CN201210142381.8A patent/CN102816157B/zh active Active
- 2006-07-26 EP EP10012967A patent/EP2301934A1/en not_active Withdrawn
- 2006-07-26 PT PT67695205T patent/PT1907382E/pt unknown
- 2006-07-26 CA CA2616377A patent/CA2616377C/en active Active
- 2006-07-26 JP JP2008523836A patent/JP5517453B2/ja active Active
- 2006-07-26 ES ES06769520.5T patent/ES2545178T3/es active Active
- 2006-07-26 BR BRPI0613859A patent/BRPI0613859B8/pt active IP Right Grant
- 2006-07-26 EP EP06769520.5A patent/EP1907382B1/en active Active
- 2006-07-26 NZ NZ565460A patent/NZ565460A/en unknown
- 2006-07-26 HU HUE06769520A patent/HUE025466T2/en unknown
- 2006-07-26 US US11/989,447 patent/US8168793B2/en active Active
- 2006-07-26 AR ARP060103235A patent/AR058439A1/es active IP Right Grant
-
2008
- 2008-01-21 IL IL188913A patent/IL188913A/en active IP Right Grant
- 2008-02-25 NO NO20080981A patent/NO341886B1/no active Protection Beyond IP Right Term
-
2012
- 2012-04-09 US US13/442,356 patent/US8907099B2/en active Active
-
2013
- 2013-03-08 JP JP2013046095A patent/JP5826201B2/ja active Active
-
2014
- 2014-11-14 US US14/541,654 patent/US9550759B2/en active Active
-
2015
- 2015-08-20 JP JP2015162861A patent/JP6280897B2/ja active Active
- 2015-08-26 CY CY20151100748T patent/CY1116754T1/el unknown
-
2016
- 2016-11-30 LU LU93327C patent/LU93327I2/fr unknown
- 2016-12-09 CY CY2016045C patent/CY2016045I1/el unknown
- 2016-12-12 NL NL300848C patent/NL300848I2/nl unknown
- 2016-12-13 LT LTPA2016036C patent/LTC1907382I2/lt unknown
- 2016-12-13 HU HUS1600056C patent/HUS000502I2/hu unknown
-
2017
- 2017-01-10 US US15/402,607 patent/US10336740B2/en active Active
-
2018
- 2018-04-11 NO NO2018013C patent/NO2018013I1/no unknown
-
2019
- 2019-06-26 US US16/452,845 patent/US20200102295A1/en not_active Abandoned
-
2022
- 2022-03-15 US US17/694,902 patent/US20220388999A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR058439A1 (es) | Derivados de nitrocatecol como inhibidores de comt. procesos de obtencion y composiciones farmaceuticas. | |
| AR060421A1 (es) | Derivados de nitrocatecol sustituidos | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20220143A1 (es) | Agonistas de glp-1r y usos de los mismos | |
| PE20080695A1 (es) | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel | |
| PE20060334A1 (es) | Derivados de piridina como antagonistas del receptor a2b de adenosina | |
| PE20120635A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR057704A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR061021A1 (es) | Derivados de ciclopropilamidas y composiciones antimicrobianas | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| PE20120229A1 (es) | Compuestos heterociclicos como inhibidores de proteasa aspartica | |
| PE20120034A1 (es) | Compuestos derivados de n-fenilpirimidin-2-amina | |
| PE20120320A1 (es) | Pirazinilpirazoles | |
| PE20080906A1 (es) | Derivados heteroarilo como inhibidores de citocina | |
| PE20070217A1 (es) | Derivados de isoquinolona sustituidos con piperidinilo | |
| PE20071171A1 (es) | Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropicos | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
| PE20080889A1 (es) | Aminometil-4-imidazoles | |
| PE20090546A1 (es) | Derivados de imidazol como antagonistas de los receptores de quimioquina ccr-2, ccr-3 y ccr-5 | |
| PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
| PE20081510A1 (es) | Derivados de dihidropiridina como inhibidores de la proteina quinasa | |
| AR051755A1 (es) | Compuestos biciclicos y triciclicos antagonistas del receptor cgrp | |
| PE20041078A1 (es) | Derivados heterociclicos inhibidores de la elastasa leucocitica humana (elh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |